Jade Biosciences (JBIO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.04B and a free-cash-flow yield of -15.8%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Middle · +31.8% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-98.7%
How far the last close sits under the highest price of the past five years.
Market cap
$1.04B
Trailing P/E
—
Price / book
2.2
Price / sales
—
FCF yield
-15.8%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
JBIO earnings
Next report: Mar 4, 2027 (Q4 2026, EPS estimate -$0.41).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 13, 2026
-$0.42
-$0.79
+46.8%
$0
Q2 2026
Aug 10, 2026
-$0.76
-$0.54
-40.7%
$0
Q1 2026
May 7, 2026
-$0.57
-$0.48
-18.8%
$0
Q3 2025
Nov 12, 2025
-$0.48
-$0.67
+28.4%
$0
JBIO analyst price target
Median target $46.00 from 8 analysts, ranging $40.00 – $77.00.
Nama's AI scorecard currently rates Jade Biosciences Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does JBIO report earnings?
Jade Biosciences's next scheduled report is on Mar 4, 2027. Analysts expect EPS of -$0.41.
What is the JBIO price target?
The median analyst price target from 8 analysts is $46.00, with a range of $40.00 – $77.00.
Is JBIO Shariah compliant?
Nama's AAOIFI-style screen reads Jade Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.